Answers are grounded in this paper and cite their sources.
Review highlights reimbursement changes for immunohistochemistry in dermatology, suggesting improved advocacy may enhance compliance.
We review recent dermatology and dermatopathology advocacy successes resulting in the reversal of immunohistochemistry (IHC) stain reimbursement denials. We also highlight a new position statement on IHC utilization, explain modifications to the Clinical Laboratory Improvement Amendments (CLIA) of 1988 and College of American Pathologists (CAP) laboratory director requirements, and outline critical legislative initiatives including support for federal payment reform for physicians.
No takes yet. Share an insight, caveat, or question.
Bridges et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: